Incyte to Establish European Headquarters in Geneva, Switzerland

Incyte to Establish European Headquarters in Geneva, Switzerland

  • New facility to serve as European base for Incyte's drug development operations
  • Location provides efficient access to key clinical trial experts and institutions


Incyte Corporation (Nasdaq:INCY) today announced that it will establish the new headquarters of Incyte Europe S.a.r.l ("Incyte Europe") in Geneva, Switzerland. Incyte intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000 sq. ft. facility by mid-2015.

"The establishment of Incyte Europe in Geneva is a natural step in our company's evolution," said Hervé Hoppenot, President and CEO of Incyte Corporation. "Incyte has a broad and growing pipeline of proprietary, wholly-owned products, and we expect that this new facility in the center of Europe will enable us to create the infrastructure needed to support our global drug development programs, and to bring additional, potentially life-changing medicines to patients with cancer."

"Geneva is especially pleased to welcome a biotechnology leader such as Incyte to our city," said, Mr. Pierre Maudet, Minister of the Department of Security and Economy for the Republic and Canton of Geneva. "We are confident that Incyte will benefit from the international talent pool in Geneva and the surrounding region, and that the company's presence will further enhance Geneva's standing as an important hub in the biotechnology industry."

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. For additional information on Incyte, please visit the Company's website at

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company's plans and expectations regarding its European headquarters, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including the results of and risks associated with: the establishment of a European headquarters; the activities and operations expected to be conducted from that headquarters; the Company's ability to create appropriate infrastructure to support its global drug development programs and help patients with cancer; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2014. Incyte disclaims any intent or obligation to update these forward-looking statements.


Incyte Corporation
Michael Booth, DPhil
Vice President, Investor Relations
+1 302-498-5914